Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes


Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.

Aim(s): To evaluate the incidence, risk factors, treatment patterns and outcomes among eligible pts.

Materials and methods: A retrospective multinational cohort of consecutive pts with advanced NEN who received at least one dose of everolimus (eve). Imaging reports were reviewed for pneumonitis (correlation between radiologic and clinical judgment). Clinical features, data on eve and treatment profiles for EiP were summarized. Overall survival was calculated with the Kaplan-Meier method.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Taboada R

Authors: Taboada R, Riechelmann R, Mauro C, Barros M, Hubner R,

Keywords: neuroendocrine, everolimus, pneumonitis,

To read the full abstract, please log into your ENETS Member account.